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Despite global efforts to reduce preventable 
maternal and neonatal mortality, Nigeria’s 
maternal mortality ratio is estimated at 576 
deaths per 100,000 live births and neonatal 
death is estimated at 37 per 1,000 live 
births 1.
Maternal and newborn deaths due to pre-eclampsia and 
eclampsia (PE/E) are preventable, yet in Nigeria this is the most 
significant direct cause of maternal deaths. 
To appreciate the enormity of this problem at country and state 
levels, a landscape analysis was conducted by the Population 
Council in 2015 on PE/E in seven states in Nigeria. The main 
objectives of the landscape analysis were: 
• To understand the level of programmatic and policy 
support for PE/E prevention and treatment;
• To analyze the gaps in providers’ knowledge and 
competence in preventing, detecting, and managing PE/E;
• To determine primary health care (PHC) facilities’ 
capacities to manage PE/E;
• To assess community awareness, beliefs, and experiences 
around PE/E;
• To understand the volume of research on PE/E in the last 
15 years; and
• To determine priority areas for research and programmatic 
interventions around PE/E.
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FINDINGS 
FROM LANDSCAPE 
ANALYSIS IN CROSS RIVER ON 
PRE-ECLAMPSIA/ECLAMPSIA
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The Ending Eclampsia project seeks to expand access                
to proven, underutilized interventions and commodities             
for the prevention, early detection, and treatment of pre-
eclampsia and eclampsia and strengthen global partnerships.
Made possible by the generous support of the 
American people through the United States Agency for 
International Development (USAID).
PE/E IN BRIEF
• Pre-eclampsia is a condition               
in pregnant women marked by an 
increase in blood pressure and 
protein in urine after 20 weeks 
gestation.
• Providing high quality antenatal care 
improves the prevention and early 
detection of pre-eclampsia and can 
prevent its progression to eclampsia.
• Eclampsia is a life-threatening 
condition characterized by 
convulsions in women with PE.
• Women in developing countries are 
300 times more likely to die from 
eclampsia than women in developed 
countries.
• Prescribing low-dose aspirin and 
calcium to at-risk women can prevent 
pre-eclampsia and eclampsia.
• Pre-eclampsia and eclampsia can 
be managed by administering anti-
hypertensive drugs and magnesium 
sulphate (MgSO4).
• MgSO4 is the safest and most 
effective treatment for severe PE/E, 
and is one of 13 UN Life-Saving 
Commodities for Women and 
Children. 
• PE/E and other hypertensive 
disorders in pregnancy increase the 
risk of pre-term births, which can 
lead to low birth weight, anemia, and 
stunting.
• Improved prevention, increased 
detection, and effective treatment 
of PE/E can prevent unnecessary 
maternal and newborn deaths.
2FIGURE 1    Proportion of facilities with key 
equipment to detect PE and manage severe PE/E
FACILITY CAPACITY & 
PREPAREDNESS
To assess institutional preparedness, researchers 
visited 11 facilities in Cross River State and recorded 
that four (36%) of the facilities had guidelines available 
for management of pre-eclampsia, two (18%) had all 
ANC equipment for the detection of PE/E and five 
(46%) use MgSO4 for the treatment of eclampsia. 
“QUOTATION. QUOTATION. 
QUOTATION. QUOTATION. 
QUOTATION. QUOTATION. 
QUOTATION. QUOTATION. 
QUOTATION.” 
—POLICYMAKER, CROSS RIVER
During these facility assessments, researchers 
determined whether the facilities had the key ANC 
equipment required to detect pre-eclampsia, manage 
severe pre-eclampsia and eclampsia, and monitor for 
MgSO4 toxicity (figure 1).
PROVIDER KNOWLEDGE & 
SKILLS
Fifty-nine healthcare providers from Cross River 
participated in the study and answered questions about 
different aspects of PE/E prevention, detection, and 
treatment. Of the providers interviewed, 50.8% could 
correctly identify chronic hypertension in pregnancy, 
while 64% correctly identified signs and symptoms of 
pre-eclampsia, yet only 5% could identify severe pre-
eclampsia, and 71% could correctly identify the signs 
and symptoms of eclampsia.
Researchers also assessed health care providers’ 
knowledge of drugs used for preventing and managing 
PE/E as well as calcium gluconate to treat MgSO4 
toxicity (figure 2).
Four (36%) facility managers reported always using 
MgSO4 to treat pre-eclampsia and eclampsia, one (9%) 
said it is sometimes used, and  six (55%) reported that 
it is never used. When asked about how they obtain 
MgSO4 supplies at the facility, the Council found that 
80% receive the drug as part of the regular central 
supply and 20% require their clients to purchase it 
from the market.
FIGURE 2    Provider knowledge of drugs for PE/E 
prevention and management (n=59)
It is clear from the results, shown in figure 2, that 
providers are unaware of the prophylactic use of 
calcium and aspirin for women at risk of pre-eclampsia: 
only two (18%) knew that anti-hypertensives (aldomet 
or nifepdipine) can be used to manage high blood 
pressure in pregnant women. 
The Pritchard regimen for MgSO4 administration is 
considered the ‘gold standard’ for preventing and 
treating convulsions in severe PE/E, but only a small 
percentage of providers (10%) could accurately 
describe the appropriate loading and maintenance 
doses of MgSO4. 
Meanwhile, only three percent of providers could name 
the appropriate antidote for MgSO4 toxicity: calcium 
gluconate. 
3FIGURE 3    Percent of clients who received all 
eight ANC components
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“QUOTATION QUOTATION 
QUOTATION QUOTATION QUOTATION 
QUOTATION QUOTATION 
QUOTATION” 
—FEMALE FGD PARTICIPANT, CROSS RIVER
SURVIVORS’ EXPERIENCES
Interviews with survivors documented their care-
seeking pathways, including their PE/E experience, 
availability and accessibility of essential services and 
commodities, and the outcomes of the pregnancy 
for mother and child. Survivors’ experiences provide 
insight informing strategies to work more closely with 
communities and health facilities improve access to, 
and use of, quality care. 
The women interviewed were similar in age, ages at 
marriage and first pregnancy, and education. 
TEXT TEXT  
“QUOTATION.”  
—PE/E SURVIVOR, CROSS RIVER
DISCUSSION
This landscape analysis identified the gaps in facilities’ 
and providers’ capacities for preventing, detecting, 
and managing PE/E; assessing community awareness, 
beliefs, and experiences of PE/E; and it determined the 
gaps and priority areas for research and programs to 
improve access to prevention and treatment. 
There are many areas of opportunity to prevent 
maternal death associated with PE/E throughout 
pregnancy, and different approaches to make the most 
of these opportunities.
In Nigeria, all easily available anti-hypertensives for 
treatment of mild to moderate hypertension (aldomet 
and nifedipine) and severe hypertension (hydralazine) 
QUALITY OF CARE
Quality of care was assessed through client provider 
observations along with client exit interviews. In 
Cross River, the Council observed 15 client-provider 
interactions during ANC visits and interviewed the 
same women after their consultations.
Clients should receive eight components of quality 
ANC care at each visit, and researchers asked the 15 
clients whether their health provider completed each 
component during the consultation (figure 3).
In addition to the eight essential components of ANC, 
questions and tests should be conducted to assess a 
woman’s risk of developing PE/E, to detect PE/E, and 
inform clients of the signs of impending eclampsia. 
During 75% of the observed ANC consultations, 
providers measured women’s BP and checked urine 
for protein. None of the providers observed, however, 
performed the necessary checks to detect women 
at risk of developing PE. These included history of 
high blood pressure (BP) and diabetes, date of last 
delivery, client’s parity, age and weight, edema of face, 
hands, legs, and ankles or advised the clients on the 
symptoms of impending eclampsia (severe headache, 
blurred vision, and pre-eclampsia with generalized 
body swelling).
COMMUNITY KNOWLEDGE & 
PERCEPTIONS
The study also included in-depth interviews (IDIs) 
and focus group discussions (FGDs) for qualitative 
information from PE/E survivors, community 
stakeholders, and families affected by PE/E. 
Misconceptions, myths, and mistrust between 
communities and health providers negatively influence 
care-seeking behaviors.
are cheap and obtainable, are often available in 
maternity emergency trays at most facilities and, if 
not, can be purchased externally. It is imperative that 
future interventions targeting providers, especially at 
primary and secondary facilities, include training on 
anti-hypertensives for pregnant women with PE/E.
For effective PE/E management, health facilities need 
to stock the necessary drugs and ANC equipment, and 
institutionalize guidelines for PE/E treatment. Providers 
need training and re-training on detecting PE/E, 
and how and when to administer appropriate drugs 
(prophylactics, anti-hypertensives, MgSO4) to prevent 
and manage it. With few providers understanding these 
elements of PE/E detection and treatment, it is not 
surprising these pregnancy complications account for 
more maternal deaths in Nigeria than any other direct 
cause, including postpartum hemorrhage 2. 
In addition to ensuring that health care providers are 
adequately trained to administer MgSO4 at the right 
time and with the proper doses, they also need to know 
the warning signs for MgSO4 toxicity and its antidote, 
calcium gluconate. 
The final, essential component to reduce mortality from 
PE/E is community awareness. Community members 
need to know the signs of PE/E and understand the 
danger it poses for mothers and babies so they can 
seek medical care promptly.
CONCLUSION
Maternal and newborn deaths due to PE/E are 
preventable: by increasing community awareness of the 
condition, improving antenatal care quality, and scaling 
up proven best practices to prevent pre-eclampsia’s 
escalation to severe pre-eclampsia and eclampsia. 
By detecting and managing pre-eclampsia, Ending 
Eclampsia can improve the survival rate of women and 
babies in Nigeria and other developing countries.
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